據報鴻海或競購新加坡半導體組裝與測試公司聯合科技
《路透》引述消息報道,蘋果(AAPL.US)代工商鴻海爲新加坡半導體組裝與測試公司聯合科技的潛在競標者,對該公司估值或達約30億美元。
聯合科技主要客戶爲「無晶圓廠」公司,即外包晶圓製造公司,以及整合元件製造商和晶圓代工廠。消息指聯合科技年度除息稅折舊攤銷前溢利(EBITDA)約爲3億美元。
消息稱,擁有聯合科技的中國私募公司智路資本已聘請富瑞負責進行銷售程序,預計月底前收到非約束性要約。由於聯合科技在中國有業務,或吸引非美國財務和戰略競標者興趣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.